MimiVax's glioblastoma vaccine falls short of Phase 2b primary endpoint

MimiVax reported that its investigational vaccine for glioblastoma did not achieve the primary efficacy goal in a Phase 2b trial.

The study, more than a decade in development, compared the vaccine with standard of care in patients with newly diagnosed glioblastoma, and the predefined endpoint was missed.

Company scientists said a modest trend toward benefit was observed in a specific patient subgroup, indicating a potential signal worth further investigation.

MimiVax said it will review the data in detail and engage regulators about possible next steps, while acknowledging the disappointment for patients and investors.